FOLH1 and prostate cancer: The Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria were introduced to fill this gap, offering a molecular imaging-based TNM (miTNM) classification for interpreting PSMA-ligand PET/CT findings.